Business Context and Reporting Period
This Form 8-K was filed by Harvard Bioscience, Inc. on September 2, 2009, reporting the completion of an asset acquisition. The Company, through its newly formed wholly-owned subsidiary DAC Acquisition Holding, Inc., acquired substantially all assets of Denville Scientific, Inc., a distributor of molecular biology products focused on liquid handling items for research laboratories.
Key Financial Metrics
- Initial Cash Payment: Approximately $12.8 million paid on September 2, 2009.
- Expected Aggregate Purchase Price: Estimated between $23 million and $24 million.
- Maximum Aggregate Purchase Price: Capped at $25.5 million under the agreement terms.
- Valuation Multiple: Approximately six times the Seller's estimated fiscal year 2009 operating profit.
- Financing Structure: The initial payment was funded by $9.0 million in borrowings under an existing credit facility with Bank of America, N.A. and Brown Brothers Harriman & Co., with the balance funded from available cash.
- Future Funding: Remaining installments are expected to be funded from existing cash balances and the credit facility.
Material Changes
The primary material change is the expansion of the Company's asset base and product distribution capabilities through the acquisition of Denville Scientific, Inc. The transaction resulted in an immediate cash outflow of $12.8 million and an increase in debt obligations of $9.0 million. The filing does not provide specific revenue, profit, or margin figures for the Company or the acquired entity for the current or prior periods, noting that financial statements for the acquired business will be filed by amendment no later than November 19, 2009.
Guidance, Outlook, and Risks
Management Commentary: The Company expects the final purchase price to fall within the $23 million to $24 million range, contingent on the Seller's 2009 financial results. A portion of the purchase price is held in escrow to secure indemnification obligations.
Contingencies and Unusual Items: The agreement includes non-competition and non-solicitation provisions binding the Seller and its principal shareholders (Walter Demsia and Ryan Sharp) for five years. An employment agreement was also entered into with Ryan Sharp. Pro forma financial information is not yet available and will be filed by November 19, 2009.
Investor Verification Checklist
- Verify the final aggregate purchase price once the 2009 financial results of Denville Scientific are finalized.
- Review the upcoming amendment to this report (due by November 19, 2009) for the financial statements of the acquired business.
- Monitor the Company's liquidity position and debt utilization following the $9.0 million draw on the credit facility.
- Assess the integration risks and the impact of the five-year non-compete agreements on future competitive dynamics.